Two new monoclonalantibodies were approved by the fda in August
👉 elranatamab bcmm, for the treatment of adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and, 👉 pozelimab bbfg, to treat patients 1 year old and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease The role of recombinant proteins in the fight against cancer and geneticdisorders of the immunesystem has become in recent […]